BioClin Therapeutics, Inc. Announces Poster Presentation of B-701 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
BioClin Therapeutics, Inc., a clinical stage drug development company announced today that data will be presented from its ongoing Phase 1b/2 study of B-701, a first-in-class anti-fibroblast growth factor receptor 3 (FGFR3) monoclonal antibody, plus docetaxel for metastatic bladder cancer at a poster session at the 2018 American Society for Clinical Oncology (ASCO) meeting being held June 1-5, 2018 in Chicago, IL.
The details of the poster presentation are as follows:
FIERCE-21: Phase 1b/2 study of Docetaxel + B-701, a Selective Inhibitor of FGFR3, in Relapsed or Refractory (R/R) Metastatic Urothelial Carcinoma (mUCC).
Joaquim Bellmunt, M.D., Ph.D., Dana-Farber Cancer Institute
Session: Genitourinary (Nonprostate) Cancer
Poster Session Date/Time: Saturday, June 3, 2018, 8:00 – 11:30 a.m., CDT, Hall A
About BioClin Therapeutics, Inc.
BioClin Therapeutics, Inc. is a privately-held clinical stage biotechnology company developing biologics to address medical conditions in areas of high unmet need. The company is focused on FGFR3 (fibroblast growth factor receptor 3), a driver mutation in metastatic bladder cancer and potentially other cancers. The company’s lead program, B-701, is the only targeted biologic specific for FGFR3 in clinical development. BioClin has ongoing clinical studies in metastatic bladder cancer including B-701 monotherapy, and B-701 in combination with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor.
For more information, please visit BioClin’s website: www.bioclintherapeutics.com
This press release contains forward-looking statements about the business and prospects of BioClin Therapeutics, Inc., which involve risks and uncertainties, including, without limitation, statements about the timing and plans to conduct clinical trials of B-701 in mUC. These risks and uncertainties include, among others: timing of enrollment in and results of the clinical trials; safety of B-701 alone or in combination with other therapies; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning B-701. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. BioClin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioClin Therapeutics, Inc.
Chief Executive Officer
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
AXILUM-ROBOTICS21.2.2019 18:02:10 | Pressemeddelelse
Axilum Robotics Announces U.S. FDA 510(k) Clearance for TMS-Cobot
MYPOS-EUROPE-LTD21.2.2019 15:59:13 | Pressemeddelelse
myPOS Presented with Best POS Innovation Award by the Merchant Payment Ecosystem
CREA-RECORDS21.2.2019 15:46:12 | Pressemeddelelse
New Release Crea Records: "ABBA We Love You Forever"
MA-ULTIVUE21.2.2019 15:32:11 | Pressemeddelelse
Ultivue Expands Global Presence with Opening of European Subsidiary, Ultivue EMEA Srl
NTT-DATA21.2.2019 15:02:09 | Pressemeddelelse
NTT DATA Launches Advanced 3D Digital Map Package for 5G Network Planning
SEOUL-SEMICONDUCTOR21.2.2019 15:02:08 | Pressemeddelelse
Seoul Semiconductor Made Global Distributor Stop Selling Everlight Product in Japan
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum